The goal of the XULTOPHY 100/3.6 REMS is to mitigate the potential risk of medullary thyroid carcinoma and the risk of acute pancreatitis (including necrotizing pancreatitis) associated with XULTOPHY 100/3.6 by:

  • Informing healthcare providers about the potential risk of medullary thyroid carcinoma associated with XULTOPHY 100/3.6.

  • Informing healthcare providers about the risk of acute pancreatitis (including necrotizing pancreatitis) associated with XULTOPHY 100/3.6.